HFG Advisors’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-605
Closed -$212K 122
2025
Q4
$212K Sell
605
-47
-7% -$15.9K 0.15% 101
2025
Q3
$211K Buy
652
+3
+0.5% +$933 0.16% 98
2025
Q2
$253K Buy
649
+2
+0.3% +$804 0.2% 80
2025
Q1
$281K Buy
647
+3
+0.5% +$1.2K 0.24% 70
2024
Q4
$238K Sell
644
-263
-29% -$110K 0.21% 79
2024
Q3
$471K Buy
907
+2
+0.2% +$1.07K 0.42% 50
2024
Q2
$490K Buy
905
+2
+0.2% +$1.06K 0.46% 48
2024
Q1
$468K Sell
903
-45
-5% -$22.4K 0.42% 54
2023
Q4
$447K Buy
948
+2
+0.2% +$925 0.43% 52
2023
Q3
$412K Buy
946
+50
+6% +$22.7K 0.45% 55
2023
Q2
$398K Buy
896
+2
+0.2% +$923 0.42% 54
2023
Q1
$411K Buy
894
+2
+0.2% +$952 0.47% 50
2022
Q4
$457K Buy
892
+2
+0.2% +$1.01K 0.54% 45
2022
Q3
$404K Sell
890
-283
-24% -$135K 0.56% 43
2022
Q2
$566K Buy
1,173
+1
+0.1% +$495 0.76% 41
2022
Q1
$575K Sell
1,172
-197
-14% -$90K 0.66% 38
2021
Q4
$635K Buy
+1,369
New +$576K 0.72% 38

Other funds holding ELV

HFG Advisors's ELV Position: Q1 2026 in Review

HFG Advisors sold out of Elevance Health (ELV) in Q1 2026, closing a stake of 605 shares — an estimated $212K sold.

HFG Advisors first reported a position in ELV in Q4 2021 and held it in 17 quarters. The position peaked at $635K in Q4 2021. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

  • HFG Advisors reported no remaining Elevance Health position as of Q1 2026 after selling out during the quarter.
  • HFG Advisors sold 605 Elevance Health shares in Q1 2026, an estimated $212K.
  • HFG Advisors first reported a position in Elevance Health in Q4 2021 and held it in 17 quarters.
  • HFG Advisors's Elevance Health position peaked at $635K in Q4 2021.
  • 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on HFG Advisors's 13F filing for Q1 2026, filed 8 May 2026.